-
Fil d’actualités
- EXPLORER
-
Pages
-
Groupes
-
Evènements
-
Blogs
-
Offres
-
Emplois
-
Courses
Viral Clearance Market Analysis by Method and Application
Valued at USD 530.34 million in 2023, the viral clearance market is projected to reach USD 592.65 million in 2024 and USD 1,464.76 million by 2032, growing at a CAGR of 12.0% during the forecast period 2024–2032. Viral clearance has become a crucial process in manufacturing biologics such as stem cell products, biosimilars, and biopharmaceuticals. Rising numbers of new drug releases, demand for biopharmaceuticals that treat chronic conditions, and expanding pharmaceutical and biotechnology industries are supporting growth, as are increasing R&D investments by government and private organizations. For B2B stakeholders, biopharmaceutical viral safety is now a core compliance priority. Key players include Merck KGaA, Sartorius AG, Charles River Laboratories, Eurofins Scientific SE, WuXi Biologics, Syngene International Limited, Kedrion, and Texcell.
Method Segmentation Shapes the Viral Clearance Market
The viral clearance market is segmented by method into viral removal, viral inactivation, and viral detection. The viral removal method accounted for the largest share in 2023, supported by its flexibility, efficiency, and cost-effectiveness, as well as its ability to adapt to novel viral threats. The viral inactivation method is projected to exhibit the highest growth rate, reflecting rising demand for plasma proteins and gene therapy products and the method's ability to deliver higher patient safety by mitigating viral contamination risk.
Nanofiltration Creates New Opportunities
Continuing advances in nanofiltration technology are expected to create lucrative opportunities. The technology is widely used in protein purification and downstream processing, offering better process control and higher safety of biopharmaceutical products. In December 2023, TeraPore Technologies announced the commercial launch of its IsoBlock VF nanofiltration product line, which leverages proprietary membrane technology. Innovations of this kind reinforce the strategic role of biopharmaceutical viral safety for manufacturers, particularly as the industry searches for scalable, dependable ways to protect patients.
Browse Insights:
https://www.polarismarketresearch.com/industry-analysis/viral-clearance-market
Application Trends: Vaccines and Advanced Therapies
By application, the market covers blood and blood products, recombinant proteins, cellular and gene therapy products, vaccines, and others. Vaccines held the majority share in 2023, driven by rising infections and chronic diseases such as cervical cancer and hepatitis. According to the Centers for Disease Control and Prevention, more than 296 million people live with hepatitis B and around 58 million with hepatitis C. Growing demand for plasma proteins and cellular and gene therapy products underpins the momentum of the viral inactivation method, while blood and blood products are projected to register the highest application growth.
Regional and End-User Insights
North America dominated in 2023, supported by leading biotechnology and medical institutes, a surge in new drug approvals, and growing production of recombinant proteins and vaccines. Asia Pacific is anticipated to be the fastest-growing region, driven by rising chronic disease and novel infection incidence, growing medical research funding, and a rising number of CROs in emerging economies. By end user, which spans pharmaceutical and biotech companies, academic research institutes, and CROs, the pharmaceutical and biotech industry led the market, while CROs are expected to grow at the highest pace as companies outsource early-phase development and laboratory testing.
Drivers, Restraints, and Strategic Outlook
Growth is propelled by increasing demand for biologics and vaccines and by rising R&D expenditure; the World Health Organization notes over a billion cases of seasonal influenza each year. Restraints include the high cost of novel viral clearance technologies and a shortage of qualified specialists. The market is moderately competitive, with players differentiating through efficacy, safety, regulatory compliance, and portfolio diversification. The report's Porter's Five Forces analysis rates the threat of new entrants as low, the bargaining power of suppliers and buyers and the threat of substitutes as moderate, and rivalry among existing firms as high. Pharmaceutical and biotech companies continue to pursue new innovations, while regulators promote the development of vaccines and drugs with improved characteristics that reduce viral contamination risks. For B2B decision-makers, strengthening capabilities across the viral removal method, the viral inactivation method, and nanofiltration technology will be central to competing in the viral clearance market through 2032.
More Trending Latest Reports By Polaris Market Research:
natural-disaster-management-market
autonomous-mobile-robot-market
benchmarking-performance-top-5-companies-in-air-purifiers
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jeux
- Gardening
- Health
- Domicile
- Literature
- Music
- Networking
- Autre
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness